Clinical Trial: A prospective, multicenter, randomized, open-label, parallel-controlled clinical study on the combination of toripalimab with PD-1 inhibitors in neoadjuvant chemoradiotherapy for locally advanced pMMR/MSS rectal cancer (China)

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, multicenter, randomized, open-label, parallel-controlled clinical study on the combination of toripalimab with PD-1 inhibitors in neoadjuvant chemoradiotherapy for locally advanced pMMR/MSS rectal cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131840

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=319903

Published by HT Digital Content Services with permission from Health Daily D...